SEARCH

SEARCH BY CITATION

References

  • 1
    Gleave ME, Ehilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998; 338: 1265-1271.
  • 2
    Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989; 63: 128-131.
  • 3
    Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol. 1992; 148: 1247-1248.
  • 4
    Marten A, Flieger D, Renoth S, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother. 2002; 51: 637-644.
  • 5
    Chang AE, Li Q, Jiang G, et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003; 21: 884-890.
  • 6
    McDermott DF, Rini BI. Immunotherapy for metastatic renal cell carcinoma. Br J Urol. 2007; 99: 1282-1288.
  • 7
    Gitlitz BJ, Belldegrun AS, Figlin RA. Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol. 2001; 19: 141-147.
  • 8
    Lesimple T, Moison A, Guille F, et al. Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte–macrophage colony-stimulating factor. J Immunother. 2000; 23: 675-679.
  • 9
    Schwabb T, Heaney JA, Schned AR, et al. A randomized phase II trial comparing 2 different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol. 2000; 163: 1322-1327.
  • 10
    Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000; 343: 750-758.
  • 11
    Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J Sci Am. 2002; 8: 2-11.
  • 12
    Rini BI, Zimmerman T, Stadler WM, et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002; 20: 2017-2024.
  • 13
    Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med. 1985; 161: 1169-1188.
  • 14
    Mule JJ, Yang JC, Lafreniere RL, et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol. 1987; 139: 285-194.
  • 15
    Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
  • 16
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
  • 17
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
  • 18
    Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007; 370: 2103-2111.
  • 19
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13: 688-696.
  • 20
    Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6: S55-S57.
  • 21
    Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998; 228: 307-319.
  • 22
    Belldegrun A, Webb DE, Austin HA III, et al. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol. 1989; 141: 499-503.
  • 23
    Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989; 7: 486-498.
  • 24
    Neidhart JA. Interferon therapy for the treatment of renal cancer. Cancer. 1986; 57: 1696-1699.
  • 25
    Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol. 1987; 14: 36-42.
  • 26
    Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006; 24: 5584-5592.
  • 27
    Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of 2 routes of administration. J Clin Oncol. 1987; 5: 286-291.
  • 28
    Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol. 2000; 18: 4009-4015.
  • 29
    Medical Research Council and Collaborators. Interferon alfa and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999; 353: 14-17.
  • 30
    Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999; 17: 2859-2867.
  • 31
    Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer [serial online]. Cochrane Database Syst Rev. 2005;( 1): CD001425.
  • 32
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med. 1998; 338: 1272-1278.
  • 33
    Yang JC, Sherry RM, Stienberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21: 3127-3132.
  • 34
    McDermott DF, Regan MM, Clark JI, et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 133-141.
  • 35
    Negrier S, Perol D, Ravaud C, et al. Medroxyprogesterone, interferon alfa-2a, interleukin-2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial. Cancer. 2007; 110: 2468-2477.
  • 36
    Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999; 17: 523-528.
  • 37
    Motzer RJ, Bacil J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002; 20: 2376-2381.
  • 38
    Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Renal cell carcinoma: histologic predictors of cytokine response. J Immunother. 2005; 28: 488-495.
  • 39
    Grabmaier K, MC AdW, Verhaegh GW, et al. Strict regulation of CAIX (G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene. 2004; 23: 5624-5631.
  • 40
    Bui MHT, Seligson D, Han K, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003; 9: 802-811.
  • 41
    Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005; 11: 3714-3721.
  • 42
    Pantuck AJ, Fang Z, Liu X, et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol. 2005; 23(16S). Abstract 4535.
  • 43
    Jaeger E, Waldman R, Roydasgupta T, et al. Array-based comparative genomic hybridization identifies chromosomal imbalances between interleukin-2 complete and non-responders [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 5043.
  • 44
    Schwarzberg T, Regan MM, Liu V, et al. Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 5044.
  • 45
    Ernstoff M, Regan MM, McDermott DF, et al. First-line therapy with bevacizumab and high dose bolus aldesleukin (IL-2) in metastatic renal cell carcinoma patients [abstract]. J Clin Oncol. 2007; 25(18S). Abstract 15524.
  • 46
    Gollob JA, Rathmell WK, Richmond T, et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-alpha2b) as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007; 25: 3288-3295.
  • 47
    Ryan CW, Goldman BH, Lara J, et al. Sorafenib plus interferon alpha2b (IFN) as first-line therapy for advanced renal cell carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007; 25: 3296-3301.
  • 48
    Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract]. Presented at: ASCO 2008 Genitourinary Cancers Symposium, February 26-28, Orlando, Florida. Abstract 350.
  • 49
    Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007; 30: 749-761.
  • 50
    Oosterwijk-Wakka JC, Tiemessen DM, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother. 2002; 25: 500-508.
  • 51
    Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006; 66: 5910-5918.
  • 52
    Yang JC, Hughes M, Kammula U, et al. Impilimumab (anti-CLTA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30: 825-830.
  • 53
    Brahmer JR, Topalian S, Wollner I, et al. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 3006.
  • 54
    Morris JC, Shapiro GI, Tan AR, et al. Phase I/II study of GC1008: a human anti-transforming growth factor-beta monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 9028.
  • 55
    Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 3007.
  • 56
    Schmidt H, Selby P, Mouritzen U, et al. Subcutaneous dosing of recombinant human interleukin-21 is safe and has clinical activity: results from a dose-escalation study in stage 4 melanoma and renal cell cancer [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 3041.
  • 57
    Moore DJ, Hwang J, McGreivy J, et al. Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors [abstract]. J Clin Oncol. 2005; 23:(16S; pt I of II). Abstract 2503.
  • 58
    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-434.